Back to Faculty

Shubham Pant

MD
Professor
The University of Texas at MD Anderson Cancer Center

Dr. Shubham Pant is a Professor in the Department of Gastrointestinal Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Pant is a key opinion leader in the fields of GI Cancers including pancreatic, biliary, gall bladder and Phase 1 trials. He also serves as the Director of Clinical Research and Associate Director for Early Phase Drug Development at the Sheikh Ahmed Bin Zayed Center. He has an expertise in Targeted therapy and Immunotherapy and has co-authored more than 100 peer-review articles and has presented research in national and international meetings including ASCO, AACR and ESMO.
Dr. Pant completed his fellowship from the James Cancer Hospital/Solove Research Institute at the Ohio State University where he was elected Chief Fellow. He has previously served as the Director of Clinical Trials, Section of Hematology/Oncology and was recipient of the Mai Eager Anderson Endowed Chair in Cancer Clinical Trials at the University Of Oklahoma.
He has been the recipient of ASCO/AACR Workshop Methods in Clinical Cancer Research and was selected for the American Society of Clinical Oncology (ASCO) Leadership Development Program. He has served as a member on the ASCO Annual Meeting Educational Committee (GI-Non Colorectal Track) and is a member of the ASCO Gastrointestinal Guidelines Committee. He has a keen interest in Global Health and held a grant through the Global Academic Program to study Gall Bladder Cancer in India and Chile.

2026 Sessions

General Session

Are RAS Inhibitors Ready for Prime Time Use as a Standard of Care in Pancreatic Cancer?: Yes vs No

Faculty will review emerging clinical and translational data targeting KRAS and related pathways, including efficacy signals, resistance mechanisms, and safety considerations, in...

  • Moderator
    • Cathy Eng, MD, FACP, FASCO
    • Yelena Janjigian, MD
  • Presenter
    • Midhun Malla, MD, MS
    • Shubham Pant, MD
Gastrointestinal Cancers

Yes

Faculty will review emerging clinical and translational data targeting KRAS and related pathways, including efficacy signals, resistance mechanisms, and safety considerations, in the treatment of pancreatic cancer. They will discuss patient selection, biomarker testing, and how these agents may integrate with existing treatment regimens, providing perspective on the readiness of RAS inhibitors to move from investigational use to routine clinical application.

This session will cover emerging clinical trial data demonstrating meaningful activity of KRAS- and RAS-targeted agents in biomarker-selected populations. The speaker will address advances in drug development, safety profiles, and integration with existing chemotherapy backbones. Participants will gain insight into how RAS inhibitors may be incorporated into routine management of pancreatic cancer.

Presenter

Sunday, March 15 2:10–2:30 PM
Room Royal Ballroom 2
Gastrointestinal Cancers

Midhun Malla

MD, MS
Associate Professor
University of Alabama

Dr. Midhun Malla, MD, MS, is an Associate Professor of Medicine at the Heersink School of Medicine and serves as Section Chief of Gastrointestinal Medical Oncology at the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham. Dr. Malla completed his fellowship training at the University of Oklahoma Health Sciences Center in Oklahoma City, where he also earned a Master’s degree in Clinical and Translational Sciences. His work is focused on advancing the role of ctDNA in precision oncology, helping to drive innovations in cancer detection and treatment. His clinical and research focus centers on hepatobiliary and colorectal cancers, with a particular emphasis on biomarker-driven clinical trials. He leads multiple prospective investigator-initiated clinical trials aimed at personalizing treatment approaches and improving outcomes for patients with Gastroiintestinal malignancies.

No

Faculty will review emerging clinical and translational data targeting KRAS and related pathways, including efficacy signals, resistance mechanisms, and safety considerations, in the treatment of pancreatic cancer. They will discuss patient selection, biomarker testing, and how these agents may integrate with existing treatment regimens, providing perspective on the readiness of RAS inhibitors to move from investigational use to routine clinical application.

Modest efficacy signals, narrow biomarker applicability, and emerging resistance mechanisms represent real concerns in the discussion of RAS inhibitor use in pancreatic cancer. Faculty will discuss safety concerns, durability of response, and unanswered questions regarding optimal sequencing and combinations to inform learners on why RAS inhibitors remain best positioned within clinical trials rather than routine practice at this time.

Presenter

Sunday, March 15 2:30–2:50 PM
Room Royal Ballroom 2
Gastrointestinal Cancers

Shubham Pant

MD
Professor
The University of Texas at MD Anderson Cancer Center

Dr. Shubham Pant is a Professor in the Department of Gastrointestinal Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Pant is a key opinion leader in the fields of GI Cancers including pancreatic, biliary, gall bladder and Phase 1 trials. He also serves as the Director of Clinical Research and Associate Director for Early Phase Drug Development at the Sheikh Ahmed Bin Zayed Center. He has an expertise in Targeted therapy and Immunotherapy and has co-authored more than 100 peer-review articles and has presented research in national and international meetings including ASCO, AACR and ESMO.
Dr. Pant completed his fellowship from the James Cancer Hospital/Solove Research Institute at the Ohio State University where he was elected Chief Fellow. He has previously served as the Director of Clinical Trials, Section of Hematology/Oncology and was recipient of the Mai Eager Anderson Endowed Chair in Cancer Clinical Trials at the University Of Oklahoma.
He has been the recipient of ASCO/AACR Workshop Methods in Clinical Cancer Research and was selected for the American Society of Clinical Oncology (ASCO) Leadership Development Program. He has served as a member on the ASCO Annual Meeting Educational Committee (GI-Non Colorectal Track) and is a member of the ASCO Gastrointestinal Guidelines Committee. He has a keen interest in Global Health and held a grant through the Global Academic Program to study Gall Bladder Cancer in India and Chile.

No

Faculty will review emerging clinical and translational data targeting KRAS and related pathways, including efficacy signals, resistance mechanisms, and safety considerations, in the treatment of pancreatic cancer. They will discuss patient selection, biomarker testing, and how these agents may integrate with existing treatment regimens, providing perspective on the readiness of RAS inhibitors to move from investigational use to routine clinical application.

Modest efficacy signals, narrow biomarker applicability, and emerging resistance mechanisms represent real concerns in the discussion of RAS inhibitor use in pancreatic cancer. Faculty will discuss safety concerns, durability of response, and unanswered questions regarding optimal sequencing and combinations to inform learners on why RAS inhibitors remain best positioned within clinical trials rather than routine practice at this time.

Presenter

Sunday, March 15 2:30–2:50 PM
Room Royal Ballroom 2
Gastrointestinal Cancers

Shubham Pant

MD
Professor
The University of Texas at MD Anderson Cancer Center

Dr. Shubham Pant is a Professor in the Department of Gastrointestinal Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Pant is a key opinion leader in the fields of GI Cancers including pancreatic, biliary, gall bladder and Phase 1 trials. He also serves as the Director of Clinical Research and Associate Director for Early Phase Drug Development at the Sheikh Ahmed Bin Zayed Center. He has an expertise in Targeted therapy and Immunotherapy and has co-authored more than 100 peer-review articles and has presented research in national and international meetings including ASCO, AACR and ESMO.
Dr. Pant completed his fellowship from the James Cancer Hospital/Solove Research Institute at the Ohio State University where he was elected Chief Fellow. He has previously served as the Director of Clinical Trials, Section of Hematology/Oncology and was recipient of the Mai Eager Anderson Endowed Chair in Cancer Clinical Trials at the University Of Oklahoma.
He has been the recipient of ASCO/AACR Workshop Methods in Clinical Cancer Research and was selected for the American Society of Clinical Oncology (ASCO) Leadership Development Program. He has served as a member on the ASCO Annual Meeting Educational Committee (GI-Non Colorectal Track) and is a member of the ASCO Gastrointestinal Guidelines Committee. He has a keen interest in Global Health and held a grant through the Global Academic Program to study Gall Bladder Cancer in India and Chile.
Back to top